Association of Irisin Circulating Level with Diabetic Retinopathy: A Case-Control Study.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association
Nafez Abu TarboushIssa N Jeris

Abstract

Obesity and obesity induced type 2 diabetes development and progression have been associated with sedentary lifestyle. Irisin, a newly discovered myokine, has been demonstrated at lower levels in obese and type 2 diabetes patients compared to controls. The main aim of this study is to explore association of Irisin with diabetic retinopathy (DR). A total of 233 healthy and adults participated in this study. Participants were divided into four categories: a healthy control group and an age-match subset of patients with type 2 diabetes; a positive control group of patients with type 2 diabetes not affected by DR (No DR); and patients with type 2 diabetes affected by DR (non-proliferative DR (NPDR) and proliferative DR (PDR)). Plasma samples were quantified for Irisin measurement, lipid profile and HbA1c. Comparison of the age-matched groups of healthy controls and patients with type 2 diabetes revealed lower Irisin plasma level in type 2 diabetes group. Analyses revealed negative correlations of Irisin to HbA1c and LDL levels and positive correlation to HDL level. Comparing Irisin level in No DR and DR groups revealed a higher level in No DR group and analysis per DR classification indicated higher Irisin level in NPDR group. Our ...Continue Reading

References

Jul 1, 1990·Diabetes Care
Jan 13, 2004·Physiological Reviews·Barbara Cannon, Jan Nedergaard
Jan 19, 2007·The New England Journal of Medicine·Parvez HossainMeguid El Nahas
May 15, 2008·American Journal of Epidemiology·Tone BjørgeGeorge Davey Smith
Jul 25, 2008·Nature·Christoph Handschin, Bruce M Spiegelman
Nov 18, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tina WenzCarlos T Moraes
Mar 1, 2012·Journal of Diabetes·Fabian Sanchis-GomarJosé L García-Giménez
Feb 2, 2013·Diabetes Research and Clinical Practice·Yeon-Kyung ChoiKeun-Gyu Park
Feb 26, 2013·The Journal of Clinical Endocrinology and Metabolism·José María Moreno-NavarreteJosé Manuel Fernández-Real
Apr 27, 2013·Journal of Diabetes and Its Complications·Jian-Jun LiuSu Chi Lim
May 15, 2013·PloS One·Ming-Shien WenKuo-Chun Hung
Dec 18, 2013·Journal of Diabetes and Its Complications·Jian-Jun LiuSu Chi Lim
Jan 9, 2014·European Journal of Endocrinology·Thomas EbertMathias Fasshauer
Jan 28, 2014·Diabetes·Jun Wu, Bruce M Spiegelman
Jan 29, 2014·Age·Karan S RanaJames E Brown
Mar 31, 2015·Annals of Clinical Biochemistry·Wenchao HuWenhui Wang
Apr 7, 2015·Neuroscience Letters·Weizhen ZhangMichael Mulholland
Apr 22, 2015·World Journal of Diabetes·Martin M Nentwich, Michael W Ulbig
Dec 18, 2015·The Review of Diabetic Studies : RDS·Alicia J JenkinsAndrzej S Januszewski
Mar 24, 2016·Journal of Cardiovascular Pharmacology·Guangxu ZhuXinghua Pan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.